Why peptides for cognition
The conventional nootropic stack — racetams, modafinil, caffeine, choline — works through stimulation or short-term neurotransmitter modulation. The peptide approach is mechanistically different: instead of pushing existing neurotransmitter pools harder, cognitive peptides act on the upstream growth factors (BDNF, NGF) and modulatory pathways (dopaminergic, GABAergic) that determine how plastic and well-functioning the underlying neural machinery is. The clinical signature is a slower onset but more durable improvement — and a far better safety profile.
The three peptides with the strongest peer-reviewed evidence — Semax, Selank, and Cerebrolysin — were all developed in Russian neuropsychiatric research programs that operate under different evidence-disclosure norms than Western pharma, so the literature is uneven in places. But the core findings have replicated across decades and (in Cerebrolysin's case) across international multicenter trials.
Semax
Semax is a heptapeptide (Met-Glu-His-Phe-Pro-Gly-Pro) derived from ACTH(4–10). It increases BDNF and NGF expression, modulates dopaminergic and noradrenergic signaling, and has neuroprotective effects in models of ischemic stroke (Skvortsova et al., 2008). Clinically, Semax has been used in Russia since 1995 for stroke recovery and is the most-prescribed nootropic in that market for cognitive complaints. The acute cognitive-activation effect — improved sustained attention, faster processing, better verbal recall — typically appears within 30–60 minutes of intranasal administration. Standard dose: 250–600 mcg intranasal, morning. Effect duration: 4–8 hours.
Selank
Selank is a synthetic heptapeptide developed by the Russian Institute of Molecular Genetics as an analog of the immune peptide tuftsin. Its primary clinical application is as an anxiolytic — and that is also why it appears on cognitive peptide lists. A large fraction of "cognitive complaints" turn out, on careful evaluation, to be anxiety-driven impairment: working memory degraded by ruminative thinking, attention fragmented by intrusive worry, slowed processing from chronic autonomic arousal. Selank addresses the input rather than the output (Medvedev et al., 2015, PMID: 26726302). Typical dose: 250–500 mcg intranasal, 2–3 times daily, 2–3 week cycles.
Cerebrolysin
Cerebrolysin is a porcine-brain-derived mixture of low-molecular-weight neuropeptides and amino acids. It has been used clinically across Europe and Asia for stroke recovery and dementia for over forty years, with a substantial multicenter clinical evidence base (Alvarez et al., Eur J Neurol, 2011, PMID: 21425947). The evidence is strongest in age-related cognitive decline; for healthy adults seeking nootropic effects, Cerebrolysin is less validated. Standard course: 10–30 ml IV daily for 4 weeks, repeated annually or biannually.
Supporting peptides
DSIP — improves sleep architecture, which is the upstream lever for all cognitive function. Epitalon — restores melatonin and circadian rhythm, secondarily improves cognition in older adults. MOTS-c — improves cellular bioenergetics; cognitive complaints with a fatigue component often respond.
Stacks
- Semax + Selank — the foundational cognitive stack. Activation plus anxiolysis.
- Semax + DSIP — for cognitive complaints driven by poor sleep architecture.
- Cerebrolysin + Semax — for age-related cognitive decline.
- Selank + Epitalon — for older adults with mixed anxiety-circadian profile.
Protocols
Beginner (single-peptide, 14 days): Semax 250 mcg morning intranasal for 14 days. Subjective rating on attention, recall, processing speed. Re-evaluate.
Intermediate (Semax + Selank, 14 days): Semax 500 mcg AM, Selank 250 mcg AM and PM, 14 days, washout 7 days, repeat as needed.
Age-related (Cerebrolysin loading, 4 weeks): Cerebrolysin 20 ml IV daily for 20 days, then maintenance Semax 250 mcg AM ongoing.
Safety
The cognitive peptides have excellent published safety profiles. Semax has no notable side effects below 1500 mcg/day. Selank can cause flattening of motivation at high doses (the dose-response is non-monotonic, which is to say more is not better). Cerebrolysin is porcine-derived; allergic or religious contraindications apply. None of these peptides produce dependence.
References
- Skvortsova VI, et al. Neuroprotective effects of Semax in ischemic stroke. 2008.
- Medvedev VE, Tereshchenko OY, et al. Selank in generalized anxiety disorder. Zh Nevrol Psikhiatr Im S S Korsakova. 2015. PMID: 26726302.
- Alvarez XA, Cacabelos R, Sampedro C, et al. Cerebrolysin in moderate to moderately severe Alzheimer's disease. Eur J Neurol. 2011. PMID: 21425947.
Versus other nootropics
The conventional nootropic landscape includes racetams (piracetam, oxiracetam, aniracetam), modafinil, methylphenidate (off-label), L-theanine plus caffeine, and a vast supplement industry around adaptogens and cholinergics. The cognitive peptides differ by acting on the upstream growth-factor and modulatory systems rather than the downstream neurotransmitter pools. The implication: slower onset, more durable effect, far better safety profile, more meaningful structural changes over multi-week protocols.
Semax in particular has a roughly four-decade Russian clinical safety record at therapeutic doses, which is more than can be said for most racetams. Selank's anxiolytic profile compares favorably to benzodiazepines (no dependency, no withdrawal, no motor impairment) and is the most-recommended peptide for cognitive complaints with a substantial anxiety component.
Specific indications
The cognitive peptides are most defensibly used for: post-concussion cognitive recovery (Semax, Cerebrolysin); cognitive complaints with anxiety-driven impairment (Selank); age-related mild cognitive impairment (Cerebrolysin, Semax); recovery from post-viral cognitive lag (Semax, often combined with MOTS-c for the metabolic-cognitive overlap); shift-worker cognitive maintenance (Semax morning dosing).
Timeline
Semax acute effects within 30–60 minutes. Selank acute effects within 1–2 hours. Cumulative effects from either build over 2–3 weeks. Cerebrolysin effects build over the 20-day loading course and consolidate 4–8 weeks after. Set evaluation milestones at 1 week, 2 weeks, 4 weeks, 8 weeks.